Tensys Medical, Inc., which designs, manufactures, and markets blood pressure monitoring systems, has entered into a commercial agreement with Zhejiang Shanshi Medical Device Co., Ltd for distribution of the company's T-Line technology.
The agreement will permit Shanshi to market, pending final regulatory approvals, the company's new TL-300 throughout China, Taiwan, and Hong Kong. Under terms of the 5-year exclusive supply relationship, the parties have agreed on cumulative orders of up to $40 million.
Shanshi will initially target the T-line into the Chinese operating room (OR) and intensive care unit (ICU) markets. The T-Line technology platform captures a patient's beat-to-beat waveform and blood pressure in a non-invasive fashion, providing physicians with a stream of real-time hemodynamic data.
"The TL-300 represents the future of hemodynamic monitoring in the Chinese market" commented Dr Xiaodong Du, Shanshi's General Manager. Dr Du added "Our pre-marketing efforts have validated our belief that the T-Line can make a dramatic impact in the Asia-Pacific hemodynamic monitoring markets and Shanshi expects to begin full marketing efforts throughout China in 2013."
The new generation TL-300 features a tablet supported monitor that allows touch screen control and displays a patient's key hemodynamic parameters. In addition to continuous beat-to-beat blood pressure and arterial waveform, the operator is readily able to view trend data for up to a 12-hour period, the company said.
"We are delighted to partner with Shanshi to commercialize our T-line platform in the Chinese critical care marketplace," commented Dr Eric Daniels, Tensys' vice president, Sales & Marketing. According to Dr Daniels, "We are confident that the T-Line has a bright future in the Asia-Pacific region and believe our relationship with Shanshi strengthens our worldwide leadership position in the field of non-invasive hemodynamic monitoring."